Advances in Multiple Myeloma: Institutional Insights from the Experts

A panel of clinical experts presents the case of a patient with high-risk multiple myeloma (MM) who underwent transplant.

Experts on multiple myeloma discuss recent updates from the GRIFFIN trial on patients with transplant-eligible multiple myeloma.

Clinical experts examine the role of transplant in multiple myeloma and discuss key clinical trials and the impact of adding daratumumab to triplet therapy.

The expert panel provides clinical insights on the key features of high-risk multiple myeloma and a look toward the clinical trial landscape.

Nausheen Ahmed, MD, discusses the measurement of treatment response following induction therapy in patients with multiple myeloma.

Experts on multiple myeloma offer clinical insights on treatment options and considerations for patients with standard- and high-risk multiple myeloma.

The standard of care for high-risk multiple myeloma remains unsettled, according to an expert panel from Kansas City.

The expert panel presents the case of a patient with multiple myeloma and discusses evaluating transplant eligibility in patients with MM.

Leyla O. Shune, MD, reviews the MAIA trial, which looked at DRd vs Rd in patients with transplant-ineligible multiple myeloma.

The expert panel gives an overview of factors that influence treatment decisions in patients with transplant-ineligible multiple myeloma.

Nausheen Ahmed, MD, and Al-Ola Abdallah, MD, discuss the use of CAR T-cell therapy in patients with transplant-ineligible multiple myeloma.

Al-Ola Abdallah, MD, presents the case of a patient with multiple myeloma treated with CAR T-cell therapy and teclistamab.

The expert panel discusses CAR T-cell therapy options and treatment considerations for patients with multiple myeloma.

Experts on multiple myeloma discuss the mechanism of action and adverse events for teclistamab and compare CAR T-cell therapy with bispecific T-cell engagers (BiTEs).

Nausheen Ahmed, MD, gives an overview of BCMA bispecific T-cell engagers used in the treatment of multiple myeloma.

The expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.